TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04277429

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac function assessment
Description: Echocardiography, cardiac enzymes analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac function assessment
Description: Echocardiography, cardiac enzymes analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac function assessment
Description: Echocardiography, cardiac enzymes analysis
Study: NCT00953784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard operating management
Description: As previously described
Study: NCT01491711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylaminolevulinate PDT in 2 sessions
Description: The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
Description: The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
Study: NCT01926366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6423
Description: Drug: AZD6423 Single or Multiple doses via infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
Study: NCT03302923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brisk walking
Description: Prospective randomized clinical trial with 2 intervention groups and 1 control group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brisk walking
Description: Prospective randomized clinical trial with 2 intervention groups and 1 control group.
Study: NCT00591786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
Study: NCT00101907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
Study: NCT00101907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
Study: NCT00851435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KBPA-101
Description: 1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
Study: NCT03485820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPASS
Description: The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
Study: NCT02759315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir 450 mg
Description: 450 mg administered as 3 x 150 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir 450 mg
Description: 450 mg administered as 3 x 150 mg oral tablets
Study: NCT02593643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study: NCT02593643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
Study: NCT02759315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir 450 mg
Description: 450 mg administered as 3 x 150 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir 60 mg
Description: 60 mg administered as 6 x 10 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir 60 mg
Description: 60 mg administered as 6 x 10 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir 60 mg
Description: 60 mg administered as 6 x 10 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir 60 mg
Description: 60 mg administered as 6 x 10 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir 60 mg
Description: 60 mg administered as 6 x 10 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir 60 mg
Description: 60 mg administered as 6 x 10 mg oral capsules
Study: NCT00286221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA fentanyl
Description: PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA fentanyl
Description: PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRN fentanyl
Description: IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRN fentanyl
Description: IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
Study: NCT02616770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1226 (4%)
Description: 3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (for 4%)
Description: 3ml saline nebulized, with Medical Air, for 2 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1226(8%)
Description: 3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (for 8%)
Description: 3ml saline nebulized, with Medical Air, for 2 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1226(12%)
Description: 3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (for 12%)
Description: 3ml saline nebulized with Medical Air for 2 minutes as a single dose
Study: NCT02771626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor
Study: NCT03485820

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stroke education
Description: The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
Study: NCT00651755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 By Vein On Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 By Vein On Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m\^2 By Vein Over 48 Hours On Days 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m\^2 By Vein Over 48 Hours On Days 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg By Vein On Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg By Vein On Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg PO for 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg PO for 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 By Vein On Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 By Vein On Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 8 mg daily for 2 days
Study: NCT04495127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib 25 mg/m2 BID
Study: NCT04289246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Ambient Display (MAD)
Description: MAD was implemented for Android tablets to provide the following external cues:~* Abstract and stylized representations of medication adherence. The MAD shows a virtual birdcage, which has the aim of raising elders' consciousness about how they have to take responsibility for caring for their health, in a way similar to willingly caring for a pet. Each day, a newborn pet grows to represent medication compliance. By touching any point on the parakeet's virtual cage, the MAD presents information on the participants' daily medication compliance.~* Auditory and visual reminders. The parakeet provides auditory reminders (a parakeet whistle) and pictograms to inform the medication to take.~After participants take their medication, they move the MAD closer to the pill container to indicate that the medication was taken. This functionality was implemented through Near Field Communication (NFC) technology. Afterward, the parakeet acknowledges that the medication was registered as taken.
Study: NCT01178593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gut-focused hypnotherapy in group sessions
Description: weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
Study: NCT03921697

Intervention type: DEVICE
Intervention: Werable sensors
Description: Parkinson Disease Patients monitored by werable sensors
Study: NCT00620815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine
Description: Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
Study: NCT02304263

Intervention type: DRUG
Intervention: iohexol
Description: 5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes

Intervention type: DRUG
Intervention: iohexol
Description: 5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
Study: NCT03807011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl group
Description: fentanyl 2 μg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil group
Description: remifentanil 0.2 μg/kg/min
Study: NCT03604042

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Protein fortifier
Description: Protein Fortifier to be added to Fortified human milk according to feeding regimen

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Protein fortifier
Description: Protein Fortifier to be added to Fortified human milk according to feeding regimen
Study: NCT03160742

Intervention type: DEVICE
Intervention: Mespere VENUS 200CVP system
Description: Non-invasive sensor placed on the neck
Study: NCT04571710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1258
Description: Drug: SHR1258 400mg
Study: NCT04130451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PYODINE AND TALC SLURRY
Description: pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PYODINE AND TALC SLURRY
Description: pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate
Study: NCT02183831

Intervention type: DEVICE
Intervention: Insertion of the capsular tension ring
Study: NCT03401983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training and Abdominal Training
Description: Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
Study: NCT02444572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 4000 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 4000 IU
Study: NCT01946997

Intervention type: OTHER
Intervention: OCT Imaging both Normal and diabetic groups
Description: Images taken to determine thickness values in the retina

Intervention type: OTHER
Intervention: OCT Imaging both Normal and diabetic groups
Description: Images taken to determine thickness values in the retina
Study: NCT01976234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh RBC
Description: Patients will receive fresh blood only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Old RBC
Study: NCT03616899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 Ophthalmic Suspension
Description: KPI-121 Ophthalmic Suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle for KPI-121 0.25% ophthalmic suspension
Study: NCT00739037

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZ-417
Study: NCT00620815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1
Description: Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine
Description: Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1
Description: Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
Description: Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine
Description: Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
Study: NCT02297620

Intervention type: DRUG
Intervention: Suglat®
Description: oral